|
Oct 15
|
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer’s Disease
|
|
Jul 29
|
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
|
|
Dec 7
|
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
|
|
Dec 5
|
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
|
|
Nov 28
|
Alpha Cognition Announces Third Quarter and Nine Months Ended September 30, 2023, Results and Provides Corporate Update
|
|
Jun 23
|
Life Science Investor Forum: Presentations Now Available for Online Viewing
|
|
Jun 20
|
Canadian Securities Exchange Reports May 2023 Performance Figures
|
|
Jun 20
|
Life Science Investor Forum Agenda Announced for June 22nd
|